{
  "meta": {
    "id": "test28",
    "title": "Mid Day Module (Medicine-1) - 2024-12-07",
    "category": "Subject Wise / Mixed"
  },
  "questions": [
    {
      "text": "A 30-year-old woman presents with complaints of polyuria (excessive urination), polydipsia (excessive thirst), and fatigue. Laboratory results reveal hyperglycemia and glucosuria. Which of the following best describes the mechanism of action of the hormone likely deficient in this patient?",
      "options": [
        {
          "label": "A",
          "text": "Activates a GPCR increasing cAMP.",
          "correct": false
        },
        {
          "label": "B",
          "text": "Directly activates PKC.",
          "correct": false
        },
        {
          "label": "C",
          "text": "Binds nuclear receptor.",
          "correct": false
        },
        {
          "label": "D",
          "text": "Interacts with tyrosine kinase receptor.",
          "correct": true
        }
      ],
      "correct_answer": "D. Interacts with tyrosine kinase receptor.",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Interacts with tyrosine kinase receptor.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Activates a GPCR increasing cAMP: This mechanism is characteristic of some Group II hormones (e.g., glucagon), but not insulin.</li><li>\u2022 Option A. Activates a GPCR increasing cAMP:</li><li>\u2022 Option B. Directly activates PKC: While PKC activation can occur downstream of insulin signaling, it is not the primary mechanism of action.</li><li>\u2022 Option B. Directly activates PKC:</li><li>\u2022 Option C. Binds nuclear receptor: This mechanism is characteristic of Group I hormones (e.g., steroid hormones, thyroid hormones)</li><li>\u2022 Option C. Binds nuclear receptor:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Insulin interacts with tyrosine kinase receptors on target cells to mediate its effects.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "088d41d6",
      "audio": ""
    },
    {
      "text": "A 45-year-old woman presents with progressive muscle weakness and a distinctive heliotrope rash around her eyes. A muscle biopsy reveals endomysial inflammation and fibrosis. Which of the following signaling pathways is most likely implicated in the pathogenesis of her condition?",
      "options": [
        {
          "label": "A",
          "text": "JAK-STAT pathway",
          "correct": false
        },
        {
          "label": "B",
          "text": "MAPK pathway",
          "correct": false
        },
        {
          "label": "C",
          "text": "PI3K/Akt pathway",
          "correct": false
        },
        {
          "label": "D",
          "text": "Smad pathway",
          "correct": true
        }
      ],
      "correct_answer": "D. Smad pathway",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/13/screenshot-2024-08-13-150602.png"
      ],
      "explanation": "<p><strong>Ans. D) Smad pathway</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. JAK-STAT pathway: This pathway is primarily involved in cytokine signaling and immune responses.</li><li>\u2022 Option A. JAK-STAT pathway:</li><li>\u2022 Option B. MAPK pathway: This pathway is involved in various cellular processes, including proliferation and differentiation, but is not the primary pathway implicated in dermatomyositis.</li><li>\u2022 Option B. MAPK pathway:</li><li>\u2022 Option C. PI3K/Akt pathway: This pathway is involved in cell survival and growth, but not the primary pathway implicated in dermatomyositis.</li><li>\u2022 Option C. PI3K/Akt pathway:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Receptor Tyrosine Kinase -  Insulin, IGF-I EGF, NGF</li><li>\u27a4 Cytokine Receptor Linked Kinase - GH, PRL</li><li>\u27a4 Serine Kinase - Activin, TGF-\u03b2, MIS</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "b3ebf911",
      "audio": ""
    },
    {
      "text": "A 30-year-old patient presents with large hands, coarse face and headache. MRI shows a pituitary tumor. Which of the following signaling pathways is most likely activated by the hormone involved in the pathology?",
      "options": [
        {
          "label": "A",
          "text": "JAK-STAT pathway",
          "correct": true
        },
        {
          "label": "B",
          "text": "MAPK pathway",
          "correct": false
        },
        {
          "label": "C",
          "text": "PI3K/Akt pathway",
          "correct": false
        },
        {
          "label": "D",
          "text": "cAMP/PKA pathway",
          "correct": false
        }
      ],
      "correct_answer": "A. JAK-STAT pathway",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) JAK-STAT pathway</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. MAPK pathway: While GH can activate MAPK pathways, it's not the primary signaling mechanism.</li><li>\u2022 Option B. MAPK pathway:</li><li>\u2022 Option C. PI3K/Akt pathway: GH also activates the PI3K/Akt pathway, but it's not the primary pathway.</li><li>\u2022 Option C. PI3K/Akt pathway:</li><li>\u2022 Option D. cAMP/PKA pathway: This pathway is primarily activated by G-protein coupled receptors, not GH receptors.</li><li>\u2022 Option D. cAMP/PKA pathway:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Growth hormone (GH) primarily signals through the JAK-STAT pathway.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "e5a73c93",
      "audio": ""
    },
    {
      "text": "Genetic testing of a patient reveals a homozygous inactivating mutation in the calcium-sensing receptor (CaSR) gene. Which of the following is the most likely diagnosis?",
      "options": [
        {
          "label": "A",
          "text": "Familial hypocalciuric hypercalcemia (FHH)",
          "correct": false
        },
        {
          "label": "B",
          "text": "Familial hypocalciuric hypocalcemia",
          "correct": false
        },
        {
          "label": "C",
          "text": "Neonatal severe hyperparathyroidism (NSHPT)",
          "correct": true
        },
        {
          "label": "D",
          "text": "Familial hypocalcemic hypercalciuria",
          "correct": false
        }
      ],
      "correct_answer": "C. Neonatal severe hyperparathyroidism (NSHPT)",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Neonatal severe hyperparathyroidism (NSHPT)</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Familial hypocalciuric hypercalcemia (FHH): FHH is a milder autosomal dominant condition caused by heterozygous CaSR mutations, characterized by mild hypercalcemia and low urinary calcium excretion.</li><li>\u2022 Option A. Familial hypocalciuric hypercalcemia (FHH):</li><li>\u2022 Option B. Familial hypocalciuric hypocalcemia: This is not a recognized condition.</li><li>\u2022 Option B. Familial hypocalciuric hypocalcemia:</li><li>\u2022 Option D. Familial hypocalcemic hypercalciuria: This is caused by activating CaSR mutations, leading to hypocalcemia and high urinary calcium excretion.</li><li>\u2022 Option D. Familial hypocalcemic hypercalciuria:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 Calcium sensing receptor defects \u2013</li><li>\u27a4 Familial hypocalciuric hypercalcemia - AD, inactivating</li><li>\u27a4 Neonatal severe hyperparathyroidism- AR, inactivating</li><li>\u27a4 Familial hypocalcemic hypercalciura- AD, activating</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "fbaab735",
      "audio": ""
    },
    {
      "text": "Which of the following steroid receptors primarily functions as a homodimer upon ligand binding?",
      "options": [
        {
          "label": "A",
          "text": "Glucocorticoid receptor (GR)",
          "correct": true
        },
        {
          "label": "B",
          "text": "Thyroid hormone receptor (TR)",
          "correct": false
        },
        {
          "label": "C",
          "text": "Vitamin D receptor (VDR)",
          "correct": false
        },
        {
          "label": "D",
          "text": "Retinoic acid receptor (RAR)",
          "correct": false
        }
      ],
      "correct_answer": "A. Glucocorticoid receptor (GR)",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/13/screenshot-2024-08-13-152909.png"
      ],
      "explanation": "<p><strong>Ans. A) Glucocorticoid receptor (GR)</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Thyroid hormone receptor (TR): TRs typically form heterodimers with retinoid X receptors (RXRs).</li><li>\u2022 Option B. Thyroid hormone receptor (TR):</li><li>\u2022 Option C. Vitamin D receptor (VDR): VDRs also primarily form heterodimers with RXRs.</li><li>\u2022 Option C. Vitamin D receptor (VDR):</li><li>\u2022 Option D. Retinoic acid receptor (RAR): RARs predominantly form heterodimers with RXRs.</li><li>\u2022 Option D. Retinoic acid receptor (RAR):</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Homodimer (Steroid) Receptors - ER, AR, PR, GR</li><li>\u27a4 Homodimer (Steroid) Receptors - ER, AR, PR, GR</li><li>\u27a4 Cytoplasmic in location. Translocates to nucleus after binding to a ligand (also called as type 1 nuclear receptors) Ligands usually induce coactivator binding</li><li>\u27a4 Cytoplasmic in location. Translocates to nucleus after binding to a ligand (also called as type 1 nuclear receptors)</li><li>\u27a4 Ligands usually induce coactivator binding</li><li>\u27a4 Heterodimer Receptors - TR, VDR, RAR, PPAR</li><li>\u27a4 Heterodimer Receptors - TR, VDR, RAR, PPAR</li><li>\u27a4 Nuclear in location (also called as type 2 nuclear receptors) Ligand dissociates corepressors and induces coactivator binding</li><li>\u27a4 Nuclear in location (also called as type 2 nuclear receptors)</li><li>\u27a4 Ligand dissociates corepressors and induces coactivator binding</li><li>\u27a4 Orphan Receptors - SF-1, DAX-1, HNF4\u03b1</li><li>\u27a4 Orphan Receptors - SF-1, DAX-1, HNF4\u03b1</li><li>\u27a4 Nuclear in location and they do not have known agonists (bind to nuclear intermediates) Action may be ligand independent & can be homo-dimeric or hetero-dimeric</li><li>\u27a4 Nuclear in location and they do not have known agonists (bind to nuclear intermediates)</li><li>\u27a4 Action may be ligand independent & can be homo-dimeric or hetero-dimeric</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "e4fae3c2",
      "audio": ""
    },
    {
      "text": "Which of the following statements is false?",
      "options": [
        {
          "label": "A",
          "text": "Thyroid hormone controls \u223c 25% of basal metabolic rate",
          "correct": false
        },
        {
          "label": "B",
          "text": "Aldosterone exerts a permissive action on other hormones.",
          "correct": true
        },
        {
          "label": "C",
          "text": "Parathyroid hormone (PTH) is a key regulator of calcium and phosphorus homeostasis.",
          "correct": false
        },
        {
          "label": "D",
          "text": "Vasopressin (ADH) is involved in the control of serum osmolality.",
          "correct": false
        }
      ],
      "correct_answer": "B. Aldosterone exerts a permissive action on other hormones.",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Aldosterone exerts a permissive action on other hormones.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Thyroid hormone: Correct. Thyroid hormone does play a significant role in regulating basal metabolic rate, affecting energy expenditure and heat production. It controls \u223c 25% of BMR in most tissues.</li><li>\u2022 Option A. Thyroid hormone:</li><li>\u2022 Option C. Parathyroid hormone (PTH): Correct. PTH is the primary regulator of calcium and phosphorus homeostasis, acting on bone, kidney, and intestine to maintain normal levels.</li><li>\u2022 Option C. Parathyroid hormone (PTH):</li><li>\u2022 Option D. Vasopressin (antidiuretic hormone): Correct. Vasopressin regulates serum osmolality by controlling water reabsorption in the kidneys, thus maintaining fluid balance.</li><li>\u2022 Option D. Vasopressin (antidiuretic hormone):</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Aldosterone does not exert a permissive action on other hormones; this function is primarily attributed to cortisol.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "dcd07ffb",
      "audio": ""
    },
    {
      "text": "Which of the following pituitary cell type would appear earliest in the fetus?",
      "options": [
        {
          "label": "A",
          "text": "Lactotrophs",
          "correct": false
        },
        {
          "label": "B",
          "text": "Gonadotrophs",
          "correct": false
        },
        {
          "label": "C",
          "text": "Thyrotrophs",
          "correct": false
        },
        {
          "label": "D",
          "text": "Corticotrophs",
          "correct": true
        }
      ],
      "correct_answer": "D. Corticotrophs",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/13/screenshot-2024-08-13-154029.png"
      ],
      "explanation": "<p><strong>Ans. D) Corticotrophs</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Lactotrophs: These cells produce prolactin and appear around 12 weeks of gestation.</li><li>\u2022 Option A. Lactotrophs:</li><li>\u2022 Option B. Gonadotrophs: These cells produce FSH and LH and also appear around 12 weeks of gestation.</li><li>\u2022 Option B. Gonadotrophs:</li><li>\u2022 Option C. Thyrotrophs: These cells produce TSH and also appear around 12 weeks of gestation.</li><li>\u2022 Option C. Thyrotrophs:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Corticotrophs are the earliest pituitary cells to appear in the fetus, around 6 weeks of gestation.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "2a55f8c0",
      "audio": ""
    },
    {
      "text": "All of the following are true about Prolactin except:",
      "options": [
        {
          "label": "A",
          "text": "Normal adult serum PRL levels are about 10\u201325 \u00b5g/mL in women",
          "correct": false
        },
        {
          "label": "B",
          "text": "Peak serum PRL levels (up to 30 \u00b5g /mL) occur between 4:00 and 6:00 a.m",
          "correct": false
        },
        {
          "label": "C",
          "text": "Highest secretory peaks occurring during rapid eye movement (REM) sleep",
          "correct": true
        },
        {
          "label": "D",
          "text": "Circulating half-life of PRL is ~50 min",
          "correct": false
        }
      ],
      "correct_answer": "C. Highest secretory peaks occurring during rapid eye movement (REM) sleep",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C)</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Normal adult serum PRL levels are about 10-25 ng/mL in women: This is the typical range for non-pregnant women. Normal serum PRL levels in men are about 10-25 ng/mL.</li><li>\u2022 Option A. Normal adult serum PRL levels are about 10-25 ng/mL in women:</li><li>\u2022 Option B. Peak serum PRL levels (up to 30 \u00b5g /mL) occur between 4:00 and 6:00 AM: Prolactin levels follow a circadian rhythm, with the highest levels occurring during the early morning hours.</li><li>\u2022 Option B. Peak serum PRL levels (up to 30 \u00b5g /mL) occur between 4:00 and 6:00 AM:</li><li>\u2022 Option D. Circulating half-life of PRL is ~50 min: Prolactin is relatively quickly cleared from the bloodstream, since it is a polypeptide.</li><li>\u2022 Option D. Circulating half-life of PRL is ~50 min:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Highest secretory peaks of prolactin occur during non-REM (NREM) sleep, not REM sleep.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "43690002",
      "audio": ""
    },
    {
      "text": "Which of the following statements is false regarding GH and IGF-1?",
      "options": [
        {
          "label": "A",
          "text": "Chronic glucocorticoid excess decreases GH release.",
          "correct": false
        },
        {
          "label": "B",
          "text": "IGF-1 inhibits GH.",
          "correct": false
        },
        {
          "label": "C",
          "text": "GH stimulates lipolysis, leading to reduced lean body mass.",
          "correct": true
        },
        {
          "label": "D",
          "text": "IGFBP3 is the major carrier protein for IGF-1.",
          "correct": false
        }
      ],
      "correct_answer": "C. GH stimulates lipolysis, leading to reduced lean body mass.",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) GH stimulates lipolysis, leading to reduced lean body mass.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Chronic glucocorticoid excess decreases GH release: Glucocorticoids can suppress GH secretion and can result in growth failure in children.</li><li>\u2022 Option A. Chronic glucocorticoid excess decreases GH release:</li><li>\u2022 Option B. IGF-1 inhibits GH: IGF-1, which is produced in response to GH, acts as a negative feedback signal to inhibit further GH release.</li><li>\u2022 Option B. IGF-1 inhibits GH:</li><li>\u2022 Option D. IGFBP3 is the major carrier protein for IGF-1: IGFBP3 is the most abundant IGF-binding protein in circulation and plays a crucial role in regulating IGF-1 bioavailability and activity.</li><li>\u2022 Option D. IGFBP3 is the major carrier protein for IGF-1:</li><li>\u2022 Summary of GH and IGF-1:</li><li>\u2022 Summary of GH and IGF-1:</li><li>\u2022 50% of anterior pituitary cell population is somatotrophs (that secrete GH) GH secretion is pulsatile and highest at night. GH secretion is increased by GHRH, ghrelin and decreased by somatostatin & IGF-1. Chronic glucocorticoid use can suppress GH secretion and can result in growth failure in children. GH secretion declines with age  (correlates with age related sarcopenia) and obesity (IGF-1 levels in obesity may be normal) GH induces insulin resistance, protein synthesis, nitrogen retention, lipolysis, and sodium and water retention. GH also promotes linear bone growth. Most GH effects are mediated indirectly through somatomedins (IGF-1 is the most important somoatomedin). IGF-1 is the major somatomedin and primarily produced in the liver in response to GH. IGF-1 is bound to IGFBPs in circulation (most important is IGFBP3). IGF-1 side effects include hypoglycemia, hypotension, fluid retention, TMJ pain, and increased intracranial pressure and possibly can cause retinal damage and avascular femoral head necrosis.</li><li>\u2022 50% of anterior pituitary cell population is somatotrophs (that secrete GH)</li><li>\u2022 GH secretion is pulsatile and highest at night.</li><li>\u2022 GH secretion is increased by GHRH, ghrelin and decreased by somatostatin & IGF-1. Chronic glucocorticoid use can suppress GH secretion and can result in growth failure in children.</li><li>\u2022 GH secretion declines with age  (correlates with age related sarcopenia) and obesity (IGF-1 levels in obesity may be normal)</li><li>\u2022 GH induces insulin resistance, protein synthesis, nitrogen retention, lipolysis, and sodium and water retention. GH also promotes linear bone growth.</li><li>\u2022 Most GH effects are mediated indirectly through somatomedins (IGF-1 is the most important somoatomedin).</li><li>\u2022 IGF-1 is the major somatomedin and primarily produced in the liver in response to GH. IGF-1 is bound to IGFBPs in circulation (most important is IGFBP3).</li><li>\u2022 IGF-1 side effects include hypoglycemia, hypotension, fluid retention, TMJ pain, and increased intracranial pressure and possibly can cause retinal damage and avascular femoral head necrosis.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 GH stimulates lipolysis, leading to an increase in lean body mass and a decrease in fat mass.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "7a005a4c",
      "audio": ""
    },
    {
      "text": "Which of the following clinical features is uncommon in Kallmann syndrome?",
      "options": [
        {
          "label": "A",
          "text": "Hyposmia",
          "correct": false
        },
        {
          "label": "B",
          "text": "Hypogonadism",
          "correct": false
        },
        {
          "label": "C",
          "text": "Mirror movements",
          "correct": false
        },
        {
          "label": "D",
          "text": "Hyperacusis",
          "correct": true
        }
      ],
      "correct_answer": "D. Hyperacusis",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Hyperacusis</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Hyposmia or anosmia: This is a hallmark feature of Kallmann syndrome.</li><li>\u2022 Option A. Hyposmia or anosmia:</li><li>\u2022 Option B. Hypogonadism: This is the primary hormonal manifestation of Kallmann syndrome.</li><li>\u2022 Option B. Hypogonadism:</li><li>\u2022 Option C. Mirror movements (bimanual synkinesis): This is a relatively common associated feature in Kallmann syndrome, although not always present.</li><li>\u2022 Option C. Mirror movements (bimanual synkinesis):</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Hyperacusis is uncommon in Kallmann syndrome, which primarily features hypogonadism and hyposmia/anosmia.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "0590ce48",
      "audio": ""
    },
    {
      "text": "What is the most common feature of adult hypopituitarism?",
      "options": [
        {
          "label": "A",
          "text": "Hypothyroidism",
          "correct": false
        },
        {
          "label": "B",
          "text": "Hypogonadism",
          "correct": true
        },
        {
          "label": "C",
          "text": "Hyperprolactinemia",
          "correct": false
        },
        {
          "label": "D",
          "text": "GH deficiency",
          "correct": false
        }
      ],
      "correct_answer": "B. Hypogonadism",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Hypogonadism</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Hypothyroidism: Common, but not as frequent as hypogonadism in adults</li><li>\u2022 Option A. Hypothyroidism:</li><li>\u2022 Option C. Hyperprolactinemia: Less common and usually associated with prolactinomas. Note that even hyperprolactinemia\u2019s are associated with hypogonadism.</li><li>\u2022 Option C. Hyperprolactinemia:</li><li>\u2022 Option D. GH deficiency: Common, but not as frequent as hypogonadism in adults</li><li>\u2022 Option D. GH deficiency:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Hypogonadism is the most common presenting feature of adult hypopituitarism.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "d17f3b18",
      "audio": ""
    },
    {
      "text": "A 32-year-old woman presents six weeks postpartum with headaches and visual disturbances. Her ESR is elevated, Prolactin levels are mildly increased, and MRI reveals a pituitary mass. Which of the following is the most likely diagnosis?",
      "options": [
        {
          "label": "A",
          "text": "Pituitary apoplexy",
          "correct": false
        },
        {
          "label": "B",
          "text": "Sheehan syndrome",
          "correct": false
        },
        {
          "label": "C",
          "text": "Lymphocytic hypophysitis",
          "correct": true
        },
        {
          "label": "D",
          "text": "Prolactinoma",
          "correct": false
        }
      ],
      "correct_answer": "C. Lymphocytic hypophysitis",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Lymphocytic hypophysitis</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Pituitary apoplexy: It is an acute hemorrhagic or ischemic event in the pituitary and presents with sudden onset of severe headache, visual loss, and ophthalmoplegia.</li><li>\u2022 Option A. Pituitary apoplexy:</li><li>\u2022 Option B. Sheehan syndrome: This is postpartum hypopituitarism caused by ischemic necrosis of the pituitary gland, usually presenting with lactational failure. Prolactin levels would be low and high ESR in this case cannot be explained by Sheehan\u2019s syndrome</li><li>\u2022 Option B. Sheehan syndrome:</li><li>\u2022 Option D. Prolactinoma: Close differential but high ESR points towards and inflammatory process than a prolactinoma. To differentiate \u2013 can consider a trial of glucocorticoids</li><li>\u2022 Option D. Prolactinoma:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Lymphocytic hypophysitis is a postpartum condition characterized by headaches, visual disturbances, elevated ESR, mildly increased prolactin levels, and MRI findings resembling a pituitary adenoma.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "38b4f17b",
      "audio": ""
    },
    {
      "text": "A 45-year-old woman with a known pituitary adenoma presents to the emergency department with sudden onset of severe headache, visual disturbances, and vomiting. Which of the following is NOT an expected complication?",
      "options": [
        {
          "label": "A",
          "text": "III cranial nerve (CN) palsy",
          "correct": false
        },
        {
          "label": "B",
          "text": "Hypertension",
          "correct": true
        },
        {
          "label": "C",
          "text": "Hypoglycaemia",
          "correct": false
        },
        {
          "label": "D",
          "text": "Visual field defects",
          "correct": false
        }
      ],
      "correct_answer": "B. Hypertension",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Hypertension</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. III CN palsy: Most common cranial nerve injured in apoplexy.</li><li>\u2022 Option A. III CN palsy:</li><li>\u2022 Option B. Hypoglycemia: Hypopituitarism can result in secondary adrenal insufficiency, leading to low cortisol levels and hypoglycemia.</li><li>\u2022 Option B. Hypoglycemia:</li><li>\u2022 Option C. Visual field defects: Compression of the optic chiasm by the pituitary mass can cause bitemporal hemianopsia or other visual field defects.</li><li>\u2022 Option C. Visual field defects:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Hypertension is not an expected complication of pituitary apoplexy.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "cb26f7be",
      "audio": ""
    },
    {
      "text": "All of the following tests are used for ACTH deficiency, except?",
      "options": [
        {
          "label": "A",
          "text": "Metyrapone test",
          "correct": false
        },
        {
          "label": "B",
          "text": "l-Arginine test",
          "correct": true
        },
        {
          "label": "C",
          "text": "CRH test",
          "correct": false
        },
        {
          "label": "D",
          "text": "ACTH stimulation test",
          "correct": false
        }
      ],
      "correct_answer": "B. l-Arginine test",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) l-Arginine test</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Metyrapone test: Tests the integrity of the hypothalamic-pituitary-adrenal (HPA) axis.</li><li>\u2022 Option A. Metyrapone test:</li><li>\u2022 Option B. CRH test: Directly stimulates the pituitary to release ACTH.</li><li>\u2022 Option B. CRH test:</li><li>\u2022 Option D. ACTH stimulation test: Assesses the adrenal glands' ability to respond to ACTH.</li><li>\u2022 Option D. ACTH stimulation test:</li><li>\u2022 Summary:</li><li>\u2022 Summary:</li><li>\u2022 Tests for ACTH deficiency:</li><li>\u2022 Tests for ACTH deficiency:</li><li>\u2022 ACTH test (Standard & low dose \u2013 test cortisol, level > 21 \u03bcg/dL is normal) Insulin tolerance test (test cortisol, level > 20 \u03bcg/dL is normal) CRH test (test ACTH and cortisol, cortisol level > 20 \u03bcg/dL is normal). Metyrapone test (test 11 deoxy cortisol and ACTH) \u2013 outdated, not in use.</li><li>\u2022 ACTH test (Standard & low dose \u2013 test cortisol, level > 21 \u03bcg/dL is normal)</li><li>\u2022 Insulin tolerance test (test cortisol, level > 20 \u03bcg/dL is normal)</li><li>\u2022 CRH test (test ACTH and cortisol, cortisol level > 20 \u03bcg/dL is normal).</li><li>\u2022 Metyrapone test (test 11 deoxy cortisol and ACTH) \u2013 outdated, not in use.</li><li>\u2022 Tests for GH deficiency: Insulin tolerance test, GHRH test, l-Arginine test, l-Dopa test, ghrelin test (macimoerlin test - ORAL) & glucagon test. Facts on Adult GH deficiency -</li><li>\u2022 Tests for GH deficiency: Insulin tolerance test, GHRH test, l-Arginine test, l-Dopa test, ghrelin test (macimoerlin test - ORAL) & glucagon test. Facts on Adult GH deficiency -</li><li>\u2022 Insulin tolerance test is the 1 st line test but C/I in diabetes, ischemic heart disease, cerebrovascular disease, epilepsy and elderly. GH >3 \u03bcg/L in response to hypoglycemia (< 40mg/dL) is considered as the normal response (GH < 3 \u03bcg/L is suggestive of GH deficiency). Adult GH deficiency is associated with changes in body composition (reduced lean body mass, increased fat mass with selective deposition of intraabdominal visceral fat, and increased waist-to-hip ratio), Hyperlipidemia, LV dysfunction, hypertension, and reduced bone mineral density. Adult hypopituitarism is associated with a 3x increase in CV mortality</li><li>\u2022 Insulin tolerance test is the 1 st line test but C/I in diabetes, ischemic heart disease, cerebrovascular disease, epilepsy and elderly.</li><li>\u2022 GH >3 \u03bcg/L in response to hypoglycemia (< 40mg/dL) is considered as the normal response (GH < 3 \u03bcg/L is suggestive of GH deficiency).</li><li>\u2022 Adult GH deficiency is associated with changes in body composition (reduced lean body mass, increased fat mass with selective deposition of intraabdominal visceral fat, and increased waist-to-hip ratio), Hyperlipidemia, LV dysfunction, hypertension, and reduced bone mineral density.</li><li>\u2022 Adult hypopituitarism is associated with a 3x increase in CV mortality</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The l-Arginine test is used to assess growth hormone (GH) reserve, not ACTH deficiency.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "0f52e54f",
      "audio": ""
    },
    {
      "text": "A 41-year-old man with a history of cranial radiation is considered for GH therapy. Which of the following is NOT a contraindication?",
      "options": [
        {
          "label": "A",
          "text": "Active neoplasm",
          "correct": false
        },
        {
          "label": "B",
          "text": "Intracranial hypertension",
          "correct": false
        },
        {
          "label": "C",
          "text": "Uncontrolled diabetes",
          "correct": false
        },
        {
          "label": "D",
          "text": "Hypertension",
          "correct": true
        }
      ],
      "correct_answer": "D. Hypertension",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Hypertension.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Active neoplasm: GH can potentially stimulate the growth of existing tumors.</li><li>\u2022 Option A. Active neoplasm:</li><li>\u2022 Option B. Intracranial hypertension: GH can worsen intracranial pressure.</li><li>\u2022 Option B. Intracranial hypertension:</li><li>\u2022 Option C. Uncontrolled diabetes: GH can impair glucose tolerance and worsen glycemic control.</li><li>\u2022 Option C. Uncontrolled diabetes:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Hypertension is not an absolute contraindication for GH therapy.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "b7b08557",
      "audio": ""
    },
    {
      "text": "A 33-year-old lady presented with headache. MRI revealed a pituitary tumor. All of the following are true except?",
      "options": [
        {
          "label": "A",
          "text": "Pituitary adenomas frequently extend in a suprasellar direction.",
          "correct": false
        },
        {
          "label": "B",
          "text": "Headache is a common feature.",
          "correct": false
        },
        {
          "label": "C",
          "text": "Headache severity correlates with adenoma size or extension.",
          "correct": true
        },
        {
          "label": "D",
          "text": "Suprasellar extension can lead to visual loss.",
          "correct": false
        }
      ],
      "correct_answer": "C. Headache severity correlates with adenoma size or extension.",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Headache severity correlates with adenoma size or extension.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Pituitary adenomas frequently extend in a suprasellar direction: Pituitary tumors often grow upwards towards the optic chiasm.</li><li>\u2022 Option A. Pituitary adenomas frequently extend in a suprasellar direction:</li><li>\u2022 Option B. Headache is a common feature: Headaches are a frequent symptom of pituitary tumors, often due to pressure effects.</li><li>\u2022 Option B. Headache is a common feature:</li><li>\u2022 Option D. Suprasellar extension can lead to visual loss: Upward growth of a pituitary tumor can compress the optic chiasm, leading to visual field defects or loss.</li><li>\u2022 Option D. Suprasellar extension can lead to visual loss:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Headache severity in pituitary adenomas does not correlate well with tumor size or extension.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "d87c0d77",
      "audio": ""
    },
    {
      "text": "A 16-year-old boy has been diagnosed with craniopharyngioma. He also has hyperphagia and obesity. This is seen in damage to which of the hypothalamic nuclei?",
      "options": [
        {
          "label": "A",
          "text": "Anterior",
          "correct": false
        },
        {
          "label": "B",
          "text": "Central",
          "correct": false
        },
        {
          "label": "C",
          "text": "Ventromedial",
          "correct": true
        },
        {
          "label": "D",
          "text": "Posterior",
          "correct": false
        }
      ],
      "correct_answer": "C. Ventromedial",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Ventromedial</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Anterior: Lesions result in Paradoxical vasoconstriction, tachycardia, and hyperthermia</li><li>\u2022 Option A. Anterior:</li><li>\u2022 Option B. Central: Lesions result in Excess sympathetic activity</li><li>\u2022 Option B. Central:</li><li>\u2022 Option D. Posterior: Lesions result in Periodic Hypothermia syndrome</li><li>\u2022 Option D. Posterior:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Damage to the ventromedial nucleus of the hypothalamus leads to hyperphagia and obesity due to loss of satiety signals.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "ed1aec3b",
      "audio": ""
    },
    {
      "text": "A 15-year-old boy presents with headaches, visual field deficits, and growth retardation. CT scan of the head is shown. What is the most likely diagnosis?",
      "options": [
        {
          "label": "A",
          "text": "Pituitary adenoma",
          "correct": false
        },
        {
          "label": "B",
          "text": "Craniopharyngioma",
          "correct": true
        },
        {
          "label": "C",
          "text": "Germinoma",
          "correct": false
        },
        {
          "label": "D",
          "text": "Pinealoma",
          "correct": false
        }
      ],
      "correct_answer": "B. Craniopharyngioma",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/13/screenshot-2024-08-13-164409.png"
      ],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/13/screenshot-2024-08-13-164911.png"
      ],
      "explanation": "<p><strong>Ans. B) Craniopharyngioma</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Pituitary adenoma: While pituitary adenomas can cause similar symptoms, they are less likely to present with calcifications and typically arise within the pituitary gland itself, not in the suprasellar region.</li><li>\u2022 Option A. Pituitary adenoma:</li><li>\u2022 Option C. Germinoma: These tumors are more common in the pineal gland and usually present with Parinaud syndrome (upward gaze palsy, pupillary abnormalities) and obstructive hydrocephalus.</li><li>\u2022 Option C. Germinoma:</li><li>\u2022 Option D. Pinealoma: These tumors arise from the pineal gland and can also present with Parinaud syndrome and obstructive hydrocephalus. They are less likely to have a cystic appearance with calcifications.</li><li>\u2022 Option D. Pinealoma:</li><li>\u2022 Important DD for sellar/suprasellar masses:</li><li>\u2022 Important DD for sellar/suprasellar masses:</li><li>\u2022 Craniopharyngioma:</li><li>\u2022 Craniopharyngioma:</li><li>\u2022 Craniopharyngioma:</li><li>\u2022 Benign, suprasellar cystic masses derived from Rathke's pouch. Presents with a triad of headaches, visual field deficits, and hypopituitarism. Presents usually < 20 years if age and the most common type is adamantinomatous (large, cystic, lobulated, locally invasive, and partially calcified, usually has CTNNB1 (\u03b2-catenin gene mutations) Hypopituitarism is seen in ~90% and diabetes insipidus in ~10%. So, most patients require lifelong pituitary hormone replacement. Treatment: Surgical resection followed by radiation of residual tumor (Surgery alone is curative in only <50% cases due to recurrences. Radiotherapy improves 10-year survival to 70-90% but slightly increases the risk of secondary malignancies). BRAF inhibitors may be effective in some cases with BRAF V600E mutations (especially in the adult papillary types).</li><li>\u2022 Benign, suprasellar cystic masses derived from Rathke's pouch.</li><li>\u2022 Presents with a triad of headaches, visual field deficits, and hypopituitarism.</li><li>\u2022 Presents usually < 20 years if age and the most common type is adamantinomatous (large, cystic, lobulated, locally invasive, and partially calcified, usually has CTNNB1 (\u03b2-catenin gene mutations)</li><li>\u2022 Hypopituitarism is seen in ~90% and diabetes insipidus in ~10%. So, most patients require lifelong pituitary hormone replacement.</li><li>\u2022 Treatment: Surgical resection followed by radiation of residual tumor (Surgery alone is curative in only <50% cases due to recurrences. Radiotherapy improves 10-year survival to 70-90% but slightly increases the risk of secondary malignancies).</li><li>\u2022 BRAF inhibitors may be effective in some cases with BRAF V600E mutations (especially in the adult papillary types).</li><li>\u2022 Rathke's Cysts:</li><li>\u2022 Rathke's Cysts:</li><li>\u2022 Rathke's Cysts:</li><li>\u2022 Occues due to failure of Rathke's pouch obliteration. Mostly asymptomatic. ~33% present in adulthood with compressive symptoms, diabetes insipidus, and hyperprolactinemia. Pathognomonic large dot sign in MRI</li><li>\u2022 Occues due to failure of Rathke's pouch obliteration.</li><li>\u2022 Mostly asymptomatic. ~33% present in adulthood with compressive symptoms, diabetes insipidus, and hyperprolactinemia.</li><li>\u2022 Pathognomonic large dot sign in MRI</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Craniopharyngiomas commonly present with headaches, visual field deficits, and growth retardation, and are characterized by suprasellar masses with calcifications on imaging.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "74960225",
      "audio": ""
    },
    {
      "text": "A 4-year-old child presents with precocious puberty, psychomotor delay, and laughing seizures. What is the first-line treatment?",
      "options": [
        {
          "label": "A",
          "text": "Surgical resection",
          "correct": false
        },
        {
          "label": "B",
          "text": "Radiotherapy",
          "correct": false
        },
        {
          "label": "C",
          "text": "GnRH analogs",
          "correct": true
        },
        {
          "label": "D",
          "text": "ACTH",
          "correct": false
        }
      ],
      "correct_answer": "C. GnRH analogs",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) GnRH analogs</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Surgical resection: Reserved for severe or refractory cases.</li><li>\u2022 Option A. Surgical resection:</li><li>\u2022 Option B. Radiotherapy: Not preferred in children due to long-term side effects.</li><li>\u2022 Option B. Radiotherapy:</li><li>\u2022 Option D. ACTH: Not relevant to precocious puberty treatment.</li><li>\u2022 Option D. ACTH:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 GnRH analogs are the first-line treatment for precocious puberty associated with hypothalamic hamartoma.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "a3427595",
      "audio": ""
    },
    {
      "text": "All of the following are familial pituitary tumour syndromes except?",
      "options": [
        {
          "label": "A",
          "text": "MEN1",
          "correct": false
        },
        {
          "label": "B",
          "text": "Carney complex",
          "correct": false
        },
        {
          "label": "C",
          "text": "MEN4",
          "correct": false
        },
        {
          "label": "D",
          "text": "Pallister hall syndrome",
          "correct": true
        }
      ],
      "correct_answer": "D. Pallister hall syndrome",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Pallister-Hall syndrome.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. MEN1 (Multiple Endocrine Neoplasia type 1): This syndrome is characterized by tumors of the parathyroid glands, pituitary gland, and pancreas.</li><li>\u2022 Option A. MEN1 (Multiple Endocrine Neoplasia type 1):</li><li>\u2022 Option B. Carney complex: This syndrome is associated with various tumors, including pituitary adenomas, cardiac myxomas, and pigmented skin lesions.</li><li>\u2022 Option B. Carney complex:</li><li>\u2022 Option C. MEN4 (Multiple Endocrine Neoplasia type 4): This rare syndrome is similar to MEN1 but is caused by mutations in a different gene (CDKN1B).</li><li>\u2022 Option C. MEN4 (Multiple Endocrine Neoplasia type 4):</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Pallister-Hall syndrome, characterized by hypothalamic hamartoma, imperforate anus, and polydactyly, is not primarily a familial pituitary tumor syndrome.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "d0038b6a",
      "audio": ""
    },
    {
      "text": "Which of the following medications is most likely to cause a significant elevation in prolactin levels, often exceeding 200 \u03bcg/L?",
      "options": [
        {
          "label": "A",
          "text": "Verapamil",
          "correct": false
        },
        {
          "label": "B",
          "text": "Methyldopa",
          "correct": false
        },
        {
          "label": "C",
          "text": "Risperidone",
          "correct": true
        },
        {
          "label": "D",
          "text": "Metoclopramide",
          "correct": false
        }
      ],
      "correct_answer": "C. Risperidone",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Risperidone</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Verapamil: While verapamil is a calcium channel blocker and can mildly elevate prolactin levels, it typically doesn't cause levels exceeding 200 \u03bcg/L.</li><li>\u2022 Option A. Verapamil:</li><li>\u2022 Option B. Methyldopa: Methyldopa is an antihypertensive that can also slightly increase prolactin, but not to the extent seen with risperidone.</li><li>\u2022 Option B. Methyldopa:</li><li>\u2022 Option D. Metoclopramide: Metoclopramide is a dopamine antagonist used for nausea and gastroparesis, and it can elevate prolactin, but typically not to levels above 200 \u03bcg/L.</li><li>\u2022 Option D. Metoclopramide:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Risperidone can significantly elevate prolactin levels, often exceeding 200 \u03bcg/L.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "92f05f5e",
      "audio": ""
    },
    {
      "text": "Which of the following is true regarding hyperprolactinemia?",
      "options": [
        {
          "label": "A",
          "text": "Falsely low PRL levels can be due to macroprolactinemia.",
          "correct": false
        },
        {
          "label": "B",
          "text": "Hook effect causes falsely elevated values of prolactin.",
          "correct": false
        },
        {
          "label": "C",
          "text": "Most common symptom in women is galactorrhea.",
          "correct": false
        },
        {
          "label": "D",
          "text": "Can be associated with reduced Bone Mineral Density.",
          "correct": true
        }
      ],
      "correct_answer": "D. Can be associated with reduced Bone Mineral Density.",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Can be associated with reduced Bone Mineral Density</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Falsely low PRL levels can be due to macroprolactinemia : Macroprolactinemia is caused by aggregated forms of circulating PRL, which are usually biologically inactive. This can result in falsely increased PRL values.</li><li>\u2022 Option A. Falsely low PRL levels can be due to</li><li>\u2022 macroprolactinemia</li><li>\u2022 Option B. Hook effect causes falsely elevated values of prolactin: Markedly elevated PRL levels (>1000 \u03bcg/L), can result in falsely low PRL values because of assay artifacts (the hook effect). Sample dilution is required to measure these high values accurately</li><li>\u2022 Option B. Hook effect causes falsely elevated values of prolactin:</li><li>\u2022 Option C. Most common symptom in women is galactorrhea: Most common symptom in women is gonadal dysfunction (galctorrhea occurs in \u223c 80% women)</li><li>\u2022 Option C. Most common symptom in women is galactorrhea:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Chronic hyperprolactinemia can reduce vertebral bone mineral density due to hypogonadism caused by prolactin suppressing GnRH release, resulting in low FSH/LH and subsequent hypoestrogenism.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "be034f1d",
      "audio": ""
    },
    {
      "text": "A 40-year-old man presents with features suggestive of acromegaly. Which of the following is incorrect?",
      "options": [
        {
          "label": "A",
          "text": "Most common cause is GH cell adenoma",
          "correct": false
        },
        {
          "label": "B",
          "text": "25% co-secrete prolactin",
          "correct": false
        },
        {
          "label": "C",
          "text": "Malignancies are the commonest cause of death",
          "correct": true
        },
        {
          "label": "D",
          "text": "Survival is 10 years lesser in acromegalics",
          "correct": false
        }
      ],
      "correct_answer": "C. Malignancies are the commonest cause of death",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Malignancies are the commonest cause of death</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Most common cause is GH cell adenoma: Common causes of acromegaly are densely or sparsely granulated GH cell adenoma (60%) > Mixed GH cell and PRL cell adenoma (25%), Mammosomatotrope cell adenoma (10%)</li><li>\u2022 Option A. Most common cause is GH cell adenoma:</li><li>\u2022 Option B. 25% co-secrete prolactin: A significant proportion of GH-secreting tumors also co-secrete prolactin, leading to symptoms such as galactorrhea and menstrual irregularities.</li><li>\u2022 Option B. 25% co-secrete prolactin:</li><li>\u2022 Option D. Survival is 10 years lesser in acromegalics: Untreated acromegaly can significantly reduce life expectancy, primarily due to cardiovascular complications.</li><li>\u2022 Option D. Survival is 10 years lesser in acromegalics:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The most common cause of death in patients with acromegaly is cardiovascular disease, not malignancies.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "6ba5421f",
      "audio": ""
    },
    {
      "text": "A 48-year-old woman with acromegaly is currently being treated with a drug but her growth hormone (GH) levels remain paradoxically elevated. Which of the following medications is she most likely taking?",
      "options": [
        {
          "label": "A",
          "text": "Octreotide",
          "correct": false
        },
        {
          "label": "B",
          "text": "Lanreotide",
          "correct": false
        },
        {
          "label": "C",
          "text": "Pegvisomant",
          "correct": true
        },
        {
          "label": "D",
          "text": "Pasireotide",
          "correct": false
        }
      ],
      "correct_answer": "C. Pegvisomant",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Pegvisomant</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Octreotide and Option B. Lanreotide: SRLs (somatostatin receptor ligand)</li><li>\u2022 Option A. Octreotide and Option B. Lanreotide:</li><li>\u2022 Reduces GH and IGF-1 levels and reduces pituitary tumor size in ~50% of patients.</li><li>\u2022 All SRLs can cause GI side effects, glucose intolerance (or diabetes), cholesterol gall stones, asymptomatic bradycardia and hypothyroxinemia.</li><li>\u2022 Octreotide is available as LAR and oral forms. Lanreotide is available as slow release depot formulation.</li><li>\u2022 Option D. Pasireotide: SRL specific for SST5 \u2013 can be used if resistant to octreotide or lanreotide. Higher prevalence of glucose intolerance and diabetes. Available as LAR.</li><li>\u2022 Option D. Pasireotide:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Pegvisomant, a GH receptor antagonist, can cause paradoxically elevated GH levels despite reducing IGF-1 production and treating symptoms of acromegaly.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "23494267",
      "audio": ""
    },
    {
      "text": "A 45-year-old male presents with complaints of excessive thirst (polydipsia) and frequent urination (polyuria), both during the day and at night. A 24-hour urine collection reveals a volume of 5 liters with an osmolality of 250 mOsm/L. Basal plasma ADH is 0.5pg/mL. MRI of the pituitary is shown. Which of the following is the most likely diagnosis?",
      "options": [
        {
          "label": "A",
          "text": "Central diabetes insipidus (DI)",
          "correct": false
        },
        {
          "label": "B",
          "text": "Nephrogenic DI",
          "correct": false
        },
        {
          "label": "C",
          "text": "Primary polydipsia",
          "correct": true
        },
        {
          "label": "D",
          "text": "Syndrome of inappropriate antidiuretic hormone secretion (SIADH)",
          "correct": false
        }
      ],
      "correct_answer": "C. Primary polydipsia",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/13/screenshot-2024-08-13-170840.png"
      ],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Primary polydipsia (DI)</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option C. Central DI: MRI would have revealed an absent posterior pituitary bright spot.</li><li>\u2022 Option C. Central DI:</li><li>\u2022 Option B. Nephrogenic DI: This is caused by resistance to ADH in the kidneys, and would typically present with ADH level of > 1pg/mL.</li><li>\u2022 Option B. Nephrogenic DI:</li><li>\u2022 Option D. SIADH (Syndrome of Inappropriate Antidiuretic Hormone Secretion): This would not cause polyuria and polydipsia.</li><li>\u2022 Option D. SIADH (Syndrome of Inappropriate Antidiuretic Hormone Secretion):</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Primary polydipsia is characterized by high urine output, low urine osmolality, low ADH levels, and an intact posterior pituitary bright spot on MRI.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "9ff62e59",
      "audio": ""
    },
    {
      "text": "A 30-year-old female with a history of psychiatric illness presents with polyuria and polydipsia. A 24-hour urine collection reveals a volume of 4 liters with an osmolality of 200 mOsm/L. Basal plasma ADH is 1.4 pg/mL. Which of the following is the best treatment?",
      "options": [
        {
          "label": "A",
          "text": "Desmopressin (DDAVP)",
          "correct": false
        },
        {
          "label": "B",
          "text": "Thiazides",
          "correct": true
        },
        {
          "label": "C",
          "text": "Fluid restriction",
          "correct": false
        },
        {
          "label": "D",
          "text": "Glucocorticoids",
          "correct": false
        }
      ],
      "correct_answer": "B. Thiazides",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Thiazides</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Desmopressin (DDAVP): This is a synthetic analog of ADH and is used to treat central DI, where there is a deficiency of ADH. It would not be effective for NDI.</li><li>\u2022 Option A. Desmopressin (DDAVP):</li><li>\u2022 Option C. Fluid restriction: Can treat SIADH but can worsen hypernatremia in NDI.</li><li>\u2022 Option C. Fluid restriction:</li><li>\u2022 Option D. Glucocorticoids: Glucocorticoids are not indicated for the treatment of DI (can worsen DI by reducing ADH release)</li><li>\u2022 Option D. Glucocorticoids:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Thiazides are the preferred treatment for nephrogenic diabetes insipidus (NDI) as they improve ADH sensitivity and reduce polyuria.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "256cfea1",
      "audio": ""
    },
    {
      "text": "A 65-year-old male smoker presents with mild confusion and nausea. He has a serum sodium of 125 mEq/L and a urine osmolality of 450 mOsm/kg. His BP and JVP are normal. Which of the following is the most appropriate initial treatment for him?",
      "options": [
        {
          "label": "A",
          "text": "Intravenous hypertonic saline (3%)",
          "correct": false
        },
        {
          "label": "B",
          "text": "Fluid restriction",
          "correct": true
        },
        {
          "label": "C",
          "text": "Demeclocycline",
          "correct": false
        },
        {
          "label": "D",
          "text": "Tolvaptan",
          "correct": false
        }
      ],
      "correct_answer": "B. Fluid restriction",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Fluid restriction</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Intravenous hypertonic saline (3%): This is reserved for severe hyponatremia (<120 mEq/L) with significant neurological symptoms (coma, seizures)</li><li>\u2022 Option A. Intravenous hypertonic saline (3%):</li><li>\u2022 Option C. Demeclocycline: This is a tetracycline antibiotic that can be used for chronic SIADH but is not the initial treatment for mild cases.</li><li>\u2022 Option C. Demeclocycline:</li><li>\u2022 Option D. Tolvaptan: This is a vasopressin receptor antagonist used for SIADH, but it is not the first-line treatment for mild cases due to its potential side effects and cost.</li><li>\u2022 Option D. Tolvaptan:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Fluid restriction is the initial treatment of choice for hyponatremia due to SIADH without severe symptoms.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "fdae53e1",
      "audio": ""
    },
    {
      "text": "A neonate presents with seizures, microcephaly, and developmental delay. Brain imaging reveals abnormalities in the white matter. Genetic testing confirms a mutation in the SLC2A1 gene. What is the treatment of choice?",
      "options": [
        {
          "label": "A",
          "text": "Ketogenic diet",
          "correct": true
        },
        {
          "label": "B",
          "text": "Prednisolone",
          "correct": false
        },
        {
          "label": "C",
          "text": "Valproate d",
          "correct": false
        },
        {
          "label": "D",
          "text": "Lamotrigine",
          "correct": false
        }
      ],
      "correct_answer": "A. Ketogenic diet",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/14/screenshot-2024-08-14-091146.png"
      ],
      "explanation": "<p><strong>Ans. A) Ketogenic diet</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Prednisolone: This is a corticosteroid used to treat inflammation and autoimmune conditions. It is not effective in GLUT1 deficiency syndrome.</li><li>\u2022 Option B. Prednisolone:</li><li>\u2022 Option C. Valproate and Option D. Lamotrigine: These are anti-seizure medications that are generally ineffective in controlling seizures associated with GLUT1 deficiency syndrome.</li><li>\u2022 Option C. Valproate</li><li>\u2022 Option D. Lamotrigine:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 GLUT1 deficiency syndrome, caused by SLC2A1 gene mutation, is best treated with a ketogenic diet to bypass glucose transport issues.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "be5641f5",
      "audio": ""
    },
    {
      "text": "Which of the following regarding insulin is correct?",
      "options": [
        {
          "label": "A",
          "text": "GLP1 and GIP reduce insulin secretion.",
          "correct": false
        },
        {
          "label": "B",
          "text": "Portal to peripheral insulin ratio is 1:1",
          "correct": false
        },
        {
          "label": "C",
          "text": "Glucose < 70 mg/dL shuts off insulin secretion.",
          "correct": true
        },
        {
          "label": "D",
          "text": "Insulin release from beta cells is glucose independent.",
          "correct": false
        }
      ],
      "correct_answer": "C. Glucose < 70 mg/dL shuts off insulin secretion.",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Glucose < 70 mg/dL shuts off insulin secretion.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. GLP1 and GIP reduce insulin secretion: GLP1 (Glucagon-like peptide-1) and GIP (Glucose-dependent insulinotropic polypeptide) are incretin hormones that actually increase insulin secretion in response to oral glucose intake.</li><li>\u2022 Option A. GLP1 and GIP reduce insulin secretion:</li><li>\u2022 Option B. Portal to peripheral insulin ratio is 1:1: The portal to peripheral insulin ratio is approximately 2:1, as a significant portion (50%) of insulin is cleared by the liver in the first pass.</li><li>\u2022 Option B. Portal to peripheral insulin ratio is 1:1:</li><li>\u2022 Option D. Insulin release from beta cells is glucose independent: This is incorrect. Glucose is the primary stimulator of insulin secretion.</li><li>\u2022 Option D. Insulin release from beta cells is glucose independent:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Glucose levels below 70 mg/dL shut off insulin secretion to prevent hypoglycemia.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "4a3d0f87",
      "audio": ""
    },
    {
      "text": "In type 1 diabetes, \u03b2 cell destruction is primarily mediated by:",
      "options": [
        {
          "label": "A",
          "text": "Antibodies",
          "correct": false
        },
        {
          "label": "B",
          "text": "CD4 T cells",
          "correct": false
        },
        {
          "label": "C",
          "text": "CD8 T cells",
          "correct": true
        },
        {
          "label": "D",
          "text": "Inflammatory cytokines",
          "correct": false
        }
      ],
      "correct_answer": "C. CD8 T cells",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) CD8 T cells</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Antibodies: Autoantibodies against beta cell antigens are present in type 1 diabetes and serve as markers of the disease, but they do not directly cause beta cell death.</li><li>\u2022 Option A. Antibodies:</li><li>\u2022 Option B. CD4 T cells: CD4 T cells play a role in activating and coordinating the immune response, but they are not the primary mediators of beta cell destruction.</li><li>\u2022 Option B. CD4 T cells:</li><li>\u2022 Option D. Inflammatory cytokines: Cytokines released by immune cells contribute to the inflammatory environment and can indirectly damage beta cells, but the direct killing is primarily mediated by CD8+ T cells.</li><li>\u2022 Option D. Inflammatory cytokines:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective :</li><li>\u27a4 CD8 T cells are the primary mediators of \u03b2 cell destruction in type 1 diabetes.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "e6d6385b",
      "audio": ""
    },
    {
      "text": "A 50-year-old patient came with the following reports. What is the likely diagnosis?",
      "options": [
        {
          "label": "A",
          "text": "Normal glucose tolerance",
          "correct": false
        },
        {
          "label": "B",
          "text": "Impaired glucose tolerance",
          "correct": false
        },
        {
          "label": "C",
          "text": "Diabetes Mellitus",
          "correct": true
        },
        {
          "label": "D",
          "text": "None of the above",
          "correct": false
        }
      ],
      "correct_answer": "C. Diabetes Mellitus",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/14/screenshot-2024-08-14-093727.png"
      ],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Diabetes Mellitus</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Normal glucose tolerance: All values should be within the normal range for this diagnosis.</li><li>\u2022 Option A. Normal glucose tolerance:</li><li>\u2022 Option B. Impaired glucose tolerance: The 2-hour PG value is too high for this diagnosis.</li><li>\u2022 Option B. Impaired glucose tolerance:</li><li>\u2022 Option D. None of the above: The correct answer is listed in the options.</li><li>\u2022 Option D. None of the above:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Diabetes Mellitus is diagnosed with fasting blood sugar \u2265126 mg/dL, 2-hour postprandial glucose \u2265200 mg/dL, or HbA1c \u22656.5%.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "76544a00",
      "audio": ""
    },
    {
      "text": "A 37-year-old obese woman presents to the clinic for a routine health evaluation. She frequently feels thirsty and wakes up at night to urinate. Which of the following studies is the most appropriate first test in evaluating this patient for diabetes mellitus?",
      "options": [
        {
          "label": "A",
          "text": "HbA1c",
          "correct": false
        },
        {
          "label": "B",
          "text": "Oral glucose tolerance test",
          "correct": false
        },
        {
          "label": "C",
          "text": "Plasma C-peptide level",
          "correct": false
        },
        {
          "label": "D",
          "text": "Random plasma glucose level",
          "correct": true
        }
      ],
      "correct_answer": "D. Random plasma glucose level",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Random plasma glucose level</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Hemoglobin A1c: While HbA1c is a valuable test for assessing long-term glycemic control, it is not the initial test of choice in a symptomatic patient.</li><li>\u2022 Option A. Hemoglobin A1c:</li><li>\u2022 Option B. Oral glucose tolerance test (OGTT): OGTT is another diagnostic test for diabetes, but it is more time-consuming and not necessary if the random plasma glucose is diagnostic.</li><li>\u2022 Option B. Oral glucose tolerance test (OGTT):</li><li>\u2022 Option C. Plasma C-peptide level: C-peptide is a marker of endogenous insulin production and is useful in distinguishing between type 1 and type 2 diabetes or evaluating hypoglycemia. It is not the first-line test for diagnosing diabetes in a symptomatic patient.</li><li>\u2022 Option C. Plasma C-peptide level:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Random plasma glucose level is the most appropriate first test for evaluating a symptomatic patient for diabetes mellitus.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "192d3c1d",
      "audio": ""
    },
    {
      "text": "Which of the following is the most common cause of pancreatic agenesis?",
      "options": [
        {
          "label": "A",
          "text": "GATA6 mutations",
          "correct": true
        },
        {
          "label": "B",
          "text": "Glucokinase mutations",
          "correct": false
        },
        {
          "label": "C",
          "text": "ABCC8 activating mutations",
          "correct": false
        },
        {
          "label": "D",
          "text": "mtDNA mutations",
          "correct": false
        }
      ],
      "correct_answer": "A. GATA6 mutations",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) GATA6 mutations</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Glucokinase mutations: Heterozygous mutations are associated with maturity-onset diabetes of the young (MODY) type 2, characterized by mild, stable hyperglycemia.</li><li>\u2022 Option B. Glucokinase mutations:</li><li>\u2022 Homozygous mutations are associated with severe neonatal diabetes.</li><li>\u2022 Homozygous mutations are associated with severe neonatal diabetes.</li><li>\u2022 Option C. ABCC8 activating mutations: These mutations cause a form of neonatal diabetes that can be treated with sulfonylureas.</li><li>\u2022 Option C. ABCC8 activating mutations:</li><li>\u2022 Option D. mtDNA mutations: Mutations in mitochondrial DNA can cause a rare form of diabetes associated with deafness, but not typically pancreatic agenesis.</li><li>\u2022 Option D. mtDNA mutations:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 GATA6 mutations are the most common cause of pancreatic agenesis.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "a25c9ca2",
      "audio": ""
    },
    {
      "text": "A 21-year-old professional gym trainer who is a known type 1 diabetic is about to start a training session. Just before the session, he notices his capillary blood glucose (CBG) to be 280 mg/dL. What should he do?",
      "options": [
        {
          "label": "A",
          "text": "Check ketones",
          "correct": true
        },
        {
          "label": "B",
          "text": "Inject insulin and exercise",
          "correct": false
        },
        {
          "label": "C",
          "text": "Avoid carbohydrates for the day",
          "correct": false
        },
        {
          "label": "D",
          "text": "Recheck CBG the next day",
          "correct": false
        }
      ],
      "correct_answer": "A. Check ketones",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Check ketones</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Inject insulin and exercise: Injecting insulin before exercise could lead to hypoglycemia during the workout, which can be dangerous.</li><li>\u2022 Option B. Inject insulin and exercise:</li><li>\u2022 Option C. Avoid carbohydrates for the day: This could also lead to hypoglycemia as carbohydrates are the primary source of energy for the body.</li><li>\u2022 Option C. Avoid carbohydrates for the day:</li><li>\u2022 Option D. Recheck CBG the next day: Delaying action on elevated blood sugar levels is not recommended and could lead to complications.</li><li>\u2022 Option D. Recheck CBG the next day:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Check for ketones before exercising if blood glucose levels are above 250 mg/dL to prevent the risk of diabetic ketoacidosis.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "62ea57d7",
      "audio": ""
    },
    {
      "text": "A 45-year-old woman with type 2 diabetes on insulin was recently started on a new drug. After a week, she presents with nausea, vomiting, abdominal pain, near-normal blood glucose, elevated anion gap metabolic acidosis, and elevated plasma ketones. Which of the following medications is the most likely cause?",
      "options": [
        {
          "label": "A",
          "text": "Metformin",
          "correct": false
        },
        {
          "label": "B",
          "text": "Canagliflozin",
          "correct": true
        },
        {
          "label": "C",
          "text": "Semaglutide",
          "correct": false
        },
        {
          "label": "D",
          "text": "Pioglitazone",
          "correct": false
        }
      ],
      "correct_answer": "B. Canagliflozin",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Canagliflozin</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Metformin: Metformin can rarely cause lactic acidosis but not associated with euDKA.</li><li>\u2022 Option A. Metformin:</li><li>\u2022 Option C. Semaglutide: Semaglutide (a GLP-1 receptor agonist) is not associated with euDKA.</li><li>\u2022 Option C. Semaglutide:</li><li>\u2022 Option D. Pioglitazone: Pioglitazone (a thiazolidinedione) is not known to cause euDKA.</li><li>\u2022 Option D. Pioglitazone:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Canagliflozin, an SGLT2 inhibitor, can cause euglycemic diabetic ketoacidosis (euDKA).</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "47ae46a2",
      "audio": ""
    },
    {
      "text": "A 55-year-old woman with type 2 diabetes mellitus and obesity presents to the clinic. She is currently taking metformin 1000 mg twice daily, but her glycemic control remains suboptimal (HbA1c 8.5%). She is interested in a medication that can help with both weight loss and glucose control. Which of the following medications would be most appropriate for this patient?",
      "options": [
        {
          "label": "A",
          "text": "Liraglutide",
          "correct": false
        },
        {
          "label": "B",
          "text": "Dulaglutide",
          "correct": false
        },
        {
          "label": "C",
          "text": "Semaglutide",
          "correct": false
        },
        {
          "label": "D",
          "text": "Tirzepatide",
          "correct": true
        }
      ],
      "correct_answer": "D. Tirzepatide",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Tirzepatide</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Liraglutide, Option B. Dulaglutide and Option C. Semaglutide: While these GLP-1 receptor agonists can promote weight loss and improve glycemic control, tirzepatide has shown superior efficacy in clinical trials compared to these options.</li><li>\u2022 Option A. Liraglutide, Option B. Dulaglutide</li><li>\u2022 Option C. Semaglutide:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Tirzepatide, a dual GIP and GLP-1 receptor agonist, is highly effective for both glycemic control and weight loss in type 2 diabetes.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "a3dd254b",
      "audio": ""
    },
    {
      "text": "A 43-year-old lady presents with a 3-month history of 7 kg weight loss despite increased appetite and nocturia. Lab reports showed a fasting blood sugar (FBS) of 331 mg/dL and an HbA1c of 11.2%. Which of the following would be the most appropriate initial therapy?",
      "options": [
        {
          "label": "A",
          "text": "Metformin",
          "correct": false
        },
        {
          "label": "B",
          "text": "Linagliptin",
          "correct": false
        },
        {
          "label": "C",
          "text": "Empagliflozin",
          "correct": false
        },
        {
          "label": "D",
          "text": "Insulin Glargine",
          "correct": true
        }
      ],
      "correct_answer": "D. Insulin Glargine",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Insulin Glargine</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Metformin: While metformin is a first-line agent for type 2 diabetes, it is not appropriate for initial therapy in patients with severe hyperglycemia or those suspected of having type 1 diabetes due to the risk of lactic acidosis.</li><li>\u2022 Option A. Metformin:</li><li>\u2022 Option B. Linagliptin: This is a DPP-4 inhibitor that increases incretin levels, promoting insulin release and decreasing glucagon secretion. It is not potent enough to manage the severe hyperglycemia in this patient.</li><li>\u2022 Option B. Linagliptin:</li><li>\u2022 Option C. Empagliflozin: This is an SGLT2 inhibitor that increases urinary glucose excretion. While it can help lower blood sugar, it can also increase the risk of euglycemic DKA, especially in patients with significant hyperglycemia.</li><li>\u2022 Option C. Empagliflozin:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Insulin is recommended for patients with severe hyperglycemia (FBS > 300 or A1C > 10%) and/or those who are symptomatic.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "472eadd3",
      "audio": ""
    },
    {
      "text": "A 45-year-old man with type 1 diabetes on insulin therapy reports waking up with high blood glucose levels despite going to bed with normal readings. Which of the following would be most helpful in determining the cause of the morning hyperglycemia?",
      "options": [
        {
          "label": "A",
          "text": "Repeat fasting blood sugar (FBS) for 3 days",
          "correct": false
        },
        {
          "label": "B",
          "text": "Do a 3 AM blood glucose check",
          "correct": true
        },
        {
          "label": "C",
          "text": "Increase evening/night time insulin dose",
          "correct": false
        },
        {
          "label": "D",
          "text": "Reduce carbohydrate intake in meals",
          "correct": false
        }
      ],
      "correct_answer": "B. Do a 3 AM blood glucose check",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Do a 3 AM blood glucose check</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Repeat FBS for 3 days: While useful for assessing overall glycemic control, it won't pinpoint the cause of the morning hyperglycemia.</li><li>\u2022 Option A. Repeat FBS for 3 days:</li><li>\u2022 Option C. Increase evening/night time insulin dose: This might be appropriate if the dawn phenomenon is confirmed, but it could worsen hypoglycemia if the Somogyi effect is the cause.</li><li>\u2022 Option C. Increase evening/night time insulin dose:</li><li>\u2022 Option D. Reduce carbohydrate intake in meals: This could help manage overall blood sugar levels but may not address the specific issue of morning hyperglycemia.</li><li>\u2022 Option D. Reduce carbohydrate intake in meals:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 A 3 AM blood glucose check helps differentiate between the Somogyi effect (nocturnal hypoglycemia) and the dawn phenomenon (early morning insulin resistance).</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "2325f7d8",
      "audio": ""
    },
    {
      "text": "A 54-year-old diabetic patient presents with breathlessness to the emergency department. On evaluation, the patient's ejection fraction (EF) is 35%. Which of the following medications should be avoided for the treatment of diabetes in this patient?",
      "options": [
        {
          "label": "A",
          "text": "Empagliflozin",
          "correct": false
        },
        {
          "label": "B",
          "text": "Dulaglutide",
          "correct": false
        },
        {
          "label": "C",
          "text": "Pioglitazone",
          "correct": true
        },
        {
          "label": "D",
          "text": "Sitagliptin",
          "correct": false
        }
      ],
      "correct_answer": "C. Pioglitazone",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Pioglitazone</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Empagliflozin (SGLT2 inhibitor): Empagliflozin has been shown to have cardioprotective effects and can be beneficial in patients with heart failure.</li><li>\u2022 Option A. Empagliflozin (SGLT2 inhibitor):</li><li>\u2022 Option B. Dulaglutide (GLP-1 receptor agonist): GLP-1 receptor agonists like dulaglutide have shown cardiovascular benefits and may be considered in patients with heart failure.</li><li>\u2022 Option B. Dulaglutide (GLP-1 receptor agonist):</li><li>\u2022 Option D. Sitagliptin (DPP-4 inhibitor): DPP-4 inhibitors are generally safe in patients with heart failure and do not have significant negative effects on cardiac function.</li><li>\u2022 Option D. Sitagliptin (DPP-4 inhibitor):</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Avoid pioglitazone in patients with symptomatic heart failure due to the risk of fluid retention and exacerbation of heart failure.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "011fde8e",
      "audio": ""
    },
    {
      "text": "Which of the following is a contraindication for vigorous exercise in individuals with diabetes?",
      "options": [
        {
          "label": "A",
          "text": "Proliferative retinopathy",
          "correct": true
        },
        {
          "label": "B",
          "text": "ESRD (End-Stage Renal Disease)",
          "correct": false
        },
        {
          "label": "C",
          "text": "Neuropathy",
          "correct": false
        },
        {
          "label": "D",
          "text": "Peripheral arterial disease",
          "correct": false
        }
      ],
      "correct_answer": "A. Proliferative retinopathy",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Proliferative retinopathy</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. ESRD (End-Stage Renal Disease): While exercise should be adjusted based on kidney function and individual tolerance, it is not an absolute contraindication.</li><li>\u2022 Option B. ESRD (End-Stage Renal Disease):</li><li>\u2022 Option C. Neuropathy: Exercise is generally encouraged in patients with diabetic neuropathy, as it can help improve nerve function and reduce pain. However, certain types of exercise may need to be modified based on the severity of neuropathy.</li><li>\u2022 Option C. Neuropathy:</li><li>\u2022 Option D. Peripheral arterial disease (PAD): Exercise can actually be beneficial for PAD as it improves circulation and reduces symptoms. However, the intensity and duration should be adjusted based on the severity of PAD and the individual's tolerance.</li><li>\u2022 Option D. Peripheral arterial disease (PAD):</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Vigorous exercise is contraindicated in individuals with proliferative retinopathy due to the risk of retinal bleeding.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "1ceb3753",
      "audio": ""
    },
    {
      "text": "Which of the following is false regarding Continuous Glucose Monitoring (CGM) in diabetes?",
      "options": [
        {
          "label": "A",
          "text": "CV (Coefficient of Variation) is an equivalent of HbA1c",
          "correct": true
        },
        {
          "label": "B",
          "text": "CGM measures interstitial glucose",
          "correct": false
        },
        {
          "label": "C",
          "text": "Low rates of hypo and hyperglycemia if used with insulin infusion device",
          "correct": false
        },
        {
          "label": "D",
          "text": "CGM can detect hypoglycemic unawareness",
          "correct": false
        }
      ],
      "correct_answer": "A. CV (Coefficient of Variation) is an equivalent of HbA1c",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) CV (Coefficient of Variation) is an equivalent of HbA1c</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. CGM measures interstitial glucose: CGM does not directly measure blood glucose. It measures glucose levels in the interstitial fluid, which closely reflects blood glucose but with a slight time lag.</li><li>\u2022 Option B. CGM measures interstitial glucose:</li><li>\u2022 Option C. Low rates of hypo and hyperglycemia if used with insulin infusion device: CGM, especially when integrated with insulin pumps (forming a hybrid closed-loop system), can significantly reduce the risk of hypoglycemia and hyperglycemia by providing real-time data and automated insulin adjustments.</li><li>\u2022 Option C. Low rates of hypo and hyperglycemia if used with insulin infusion device:</li><li>\u2022 Option D. CGM can detect hypoglycemic unawareness: CGM can alert patients to impending hypoglycemia, even if they are not experiencing typical symptoms, thus helping to prevent severe hypoglycemic events.</li><li>\u2022 Option D. CGM can detect hypoglycemic unawareness:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Coefficient of Variation (CV) measures glucose variability and is not equivalent to HbA1c.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "d533f140",
      "audio": ""
    },
    {
      "text": "Which of the following is incorrect regarding glycemic targets in non-pregnant diabetics?",
      "options": [
        {
          "label": "A",
          "text": "Preprandial 80-130 mg/dL",
          "correct": false
        },
        {
          "label": "B",
          "text": "Postprandial < 180 mg/dL",
          "correct": false
        },
        {
          "label": "C",
          "text": "HbA1C < 7%",
          "correct": false
        },
        {
          "label": "D",
          "text": "Goals should be more stringent in older adults",
          "correct": true
        }
      ],
      "correct_answer": "D. Goals should be more stringent in older adults",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/14/screenshot-2024-08-14-095420.png"
      ],
      "explanation": "<p><strong>Ans. D) Goals should be more stringent in older adults</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Preprandial 80-130 mg/dL: This is the correct target range for preprandial capillary plasma glucose according to the ADA guidelines.</li><li>\u2022 Option A. Preprandial 80-130 mg/dL:</li><li>\u2022 Option B. Postprandial < 180 mg/dL: This is the correct target range for peak postprandial capillary plasma glucose according to the ADA guidelines.</li><li>\u2022 Option B. Postprandial < 180 mg/dL:</li><li>\u2022 Option C. HbA1C < 7%: This is the general target for HbA1c in most non-pregnant adults with diabetes.</li><li>\u2022 Option C. HbA1C < 7%:</li><li>\u2022 Summary:</li><li>\u2022 Summary:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Glycemic targets in older adults should be less stringent due to increased risk of hypoglycemia.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "74d60907",
      "audio": ""
    },
    {
      "text": "A 45-year-old woman from Chennai presents with a waist circumference of 92 cm, a blood pressure of 120/80 mmHg, and a fasting blood glucose of 110 mg/dL. Which of the following additional findings would be needed to diagnose metabolic syndrome?",
      "options": [
        {
          "label": "A",
          "text": "HDL cholesterol level of 58 mg/dL",
          "correct": false
        },
        {
          "label": "B",
          "text": "Triglyceride level of 160 mg/dL",
          "correct": true
        },
        {
          "label": "C",
          "text": "Taking a statin for hypercholesterolemia",
          "correct": false
        },
        {
          "label": "D",
          "text": "BMI of 28 kg/m\u00b2",
          "correct": false
        }
      ],
      "correct_answer": "B. Triglyceride level of 160 mg/dL",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/14/screenshot-2024-08-14-100019.png"
      ],
      "explanation": "<p><strong>Ans. B) Triglyceride level of 160 mg/dL</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. HDL cholesterol level of 58 mg/dL: This is within normal limits (>50 mg/dL) and does not contribute to the diagnosis of metabolic syndrome.</li><li>\u2022 Option A. HDL cholesterol level of 58 mg/dL:</li><li>\u2022 Option C. Taking a statin for hypercholesterolemia: This is a treatment for high cholesterol but is not a diagnostic criterion for metabolic syndrome.</li><li>\u2022 Option C. Taking a statin for hypercholesterolemia:</li><li>\u2022 Option D. BMI of 28 kg/m\u00b2: This is considered overweight but not obese, and while it can be associated with metabolic syndrome, it is not a direct diagnostic criterion.</li><li>\u2022 Option D. BMI of 28 kg/m\u00b2:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Metabolic syndrome diagnosis requires at least three criteria, including central obesity, elevated triglycerides, low HDL cholesterol, high blood pressure, or high fasting glucose.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "91eace8b",
      "audio": ""
    },
    {
      "text": "Patients with metabolic syndrome are at higher risk for all of the following EXCEPT:",
      "options": [
        {
          "label": "A",
          "text": "Alzheimer\u2019s disease",
          "correct": true
        },
        {
          "label": "B",
          "text": "Gout",
          "correct": false
        },
        {
          "label": "C",
          "text": "Non-alcoholic fatty liver disease",
          "correct": false
        },
        {
          "label": "D",
          "text": "Polycystic ovarian syndrome",
          "correct": false
        }
      ],
      "correct_answer": "A. Alzheimer\u2019s disease",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Alzheimer's disease</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Gout: The metabolic syndrome is associated with increased uric acid levels, a key risk factor for gout.</li><li>\u2022 Option B. Gout:</li><li>\u2022 Option C. Nonalcoholic fatty liver disease (NAFLD): Insulin resistance, a central feature of metabolic syndrome, is strongly linked to the development of NAFLD.</li><li>\u2022 Option C. Nonalcoholic fatty liver disease (NAFLD):</li><li>\u2022 Option D. Polycystic ovarian syndrome (PCOS): Insulin resistance is also a key factor in the development of PCOS, and metabolic syndrome is frequently seen in women with PCOS.</li><li>\u2022 Option D. Polycystic ovarian syndrome (PCOS):</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Metabolic syndrome is linked with gout, non-alcoholic fatty liver disease, and polycystic ovarian syndrome but not strongly with Alzheimer's disease.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "ac68aea9",
      "audio": ""
    },
    {
      "text": "Which of the following is reduced in obese patients?",
      "options": [
        {
          "label": "A",
          "text": "Leptin",
          "correct": false
        },
        {
          "label": "B",
          "text": "Adiponectin",
          "correct": true
        },
        {
          "label": "C",
          "text": "Insulin",
          "correct": false
        },
        {
          "label": "D",
          "text": "TNF-\u03b1",
          "correct": false
        }
      ],
      "correct_answer": "B. Adiponectin",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Adiponectin</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Leptin: Leptin levels are typically elevated in obese patients, but its signaling is often impaired (leptin resistance). Elevated leptin is associated with endothelial damage resulting in CV risk.</li><li>\u2022 Option A. Leptin:</li><li>\u2022 Option C. Insulin: Insulin levels are often elevated in obese patients due to insulin resistance.</li><li>\u2022 Option C. Insulin:</li><li>\u2022 Option D. TNF-\u03b1: TNF-\u03b1 (and IL-6) is increased in obesity, contributing to the chronic low-grade inflammation, which can cause endothelial injury and increase CV risk.</li><li>\u2022 Option D. TNF-\u03b1:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Adiponectin levels are reduced in obese patients, contributing to insulin resistance and metabolic syndrome.</li><li>\u27a4 Adipokines in Obesity:</li><li>\u27a4 Adipokines in Obesity:</li><li>\u27a4 Increased: Leptin, Insulin, Resistin, Proinflammatory cytokines (IL6/ TNF \u03b1) Decreased : Adiponectin, Ghrelin</li><li>\u27a4 Increased: Leptin, Insulin, Resistin, Proinflammatory cytokines (IL6/ TNF \u03b1)</li><li>\u27a4 Decreased : Adiponectin, Ghrelin</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "3bb2814f",
      "audio": ""
    },
    {
      "text": "Which of the following is true regarding Prader Willi Syndrome (PWS)?",
      "options": [
        {
          "label": "A",
          "text": "Most common mechanism of imprinting center mutations",
          "correct": false
        },
        {
          "label": "B",
          "text": "Loss of SNRPN gene",
          "correct": true
        },
        {
          "label": "C",
          "text": "Inherited in autosomal dominant pattern",
          "correct": false
        },
        {
          "label": "D",
          "text": "Reduced Ghrelin",
          "correct": false
        }
      ],
      "correct_answer": "B. Loss of SNRPN gene",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Loss of SNRPN gene</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Most common mechanism of imprinting center mutations: While imprinting center mutations can cause PWS, the most common mechanism is a deletion of the paternal 15q11-q13 region (about 70% of cases). 25% cases are due to maternal uniparental disomy and < 1% cases are due to imprinting center mutations. FISH is the 1 st line diagnostic test in PWS.</li><li>\u2022 Option A. Most common mechanism of imprinting center mutations:</li><li>\u2022 Option C. Inherited in autosomal dominant pattern: Most cases of PWS are sporadic and do not show Mendelian inheritance.</li><li>\u2022 Option C. Inherited in autosomal dominant pattern:</li><li>\u2022 Option D. Reduced Ghrelin: Ghrelin levels are actually elevated in individuals with PWS, contributing to their hyperphagia and obesity. Patients with PWS also show reduced BDNF expression, contributing to hyperphagia.</li><li>\u2022 Option D. Reduced Ghrelin:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Prader-Willi syndrome is primarily caused by the loss of the SNRPN gene, leading to hyperphagia and obesity.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "ca91396e",
      "audio": ""
    },
    {
      "text": "Which of the following drugs is not approved for general obesity?",
      "options": [
        {
          "label": "A",
          "text": "Semaglutide",
          "correct": false
        },
        {
          "label": "B",
          "text": "Setmelanotide",
          "correct": true
        },
        {
          "label": "C",
          "text": "Orlistat",
          "correct": false
        },
        {
          "label": "D",
          "text": "Phentermine",
          "correct": false
        }
      ],
      "correct_answer": "B. Setmelanotide",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Setmelanotide</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Semaglutide: This GLP-1 receptor agonist is approved for chronic weight management in adults with general obesity.</li><li>\u2022 Option A. Semaglutide:</li><li>\u2022 Option C. Orlistat: This lipase inhibitor is approved for weight loss in adults and adolescents with obesity.</li><li>\u2022 Option C. Orlistat:</li><li>\u2022 Option D. Phentermine: This appetite suppressant is approved for short-term use in adults with obesity.</li><li>\u2022 Option D. Phentermine:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Setmelanotide is not approved for general obesity but for specific genetic conditions like POMC deficiency, LEPR deficiency, and Bardet-Biedl syndrome.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "dbc9c289",
      "audio": ""
    },
    {
      "text": "A 32-year-old woman with a BMI of 31 kg/m\u00b2 and no obesity-related comorbidities is seeking advice on weight management. What is the most appropriate initial intervention for this patient?",
      "options": [
        {
          "label": "A",
          "text": "Pharmacotherapy",
          "correct": false
        },
        {
          "label": "B",
          "text": "Bariatric surgery",
          "correct": false
        },
        {
          "label": "C",
          "text": "Diet, exercise, and behavioral therapy",
          "correct": true
        },
        {
          "label": "D",
          "text": "No intervention needed",
          "correct": false
        }
      ],
      "correct_answer": "C. Diet, exercise, and behavioral therapy",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/14/screenshot-2024-08-14-104442.png"
      ],
      "explanation": "<p><strong>Ans. C) Diet, exercise, and behavioral therapy</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Pharmacotherapy: While pharmacotherapy can be an adjunct to lifestyle modification for weight loss, it is not the first-line treatment for patients with obesity class I without comorbidities.</li><li>\u2022 Option A. Pharmacotherapy:</li><li>\u2022 Option B. Bariatric surgery: Bariatric surgery is reserved for patients with severe obesity (BMI \u2265 40 kg/m\u00b2) or those with BMI \u2265 35 kg/m\u00b2 and significant comorbidities.</li><li>\u2022 Option B. Bariatric surgery:</li><li>\u2022 Option D. No intervention needed: Although the patient does not have any current comorbidities, a BMI of 31 kg/m\u00b2 puts her at risk for developing obesity-related health problems in the future. Therefore, intervention is recommended to prevent these complications.</li><li>\u2022 Option D. No intervention needed:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The initial intervention for patients with class I obesity without comorbidities should be diet, exercise, and behavioral therapy.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "295ec23b",
      "audio": ""
    },
    {
      "text": "Which of the following preparations of insulin has the longest time to onset and the longest duration of action?",
      "options": [
        {
          "label": "A",
          "text": "Aspart",
          "correct": false
        },
        {
          "label": "B",
          "text": "Glargine",
          "correct": true
        },
        {
          "label": "C",
          "text": "NPH",
          "correct": false
        },
        {
          "label": "D",
          "text": "Regular",
          "correct": false
        }
      ],
      "correct_answer": "B. Glargine",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/14/screenshot-2024-08-14-123019.png",
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/14/screenshot-2024-08-14-123213.png"
      ],
      "explanation": "<p><strong>Ans. B) Glargine</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Aspart: This is a rapid-acting insulin analog with a quick onset (15-30 minutes) and short duration (3-5 hours).</li><li>\u2022 Option A. Aspart:</li><li>\u2022 Option C. NPH: This is an intermediate-acting insulin with a slower onset (1-2 hours) and moderate duration (12-18 hours).</li><li>\u2022 Option C. NPH:</li><li>\u2022 Option D. Regular: This is a short-acting insulin with a relatively quick onset (30-60 minutes) and shorter duration (5-8 hours).</li><li>\u2022 Option D. Regular:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Glargine is a long-acting insulin analog with a slow onset (1-2 hours) and prolonged duration (20-24 hours).</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "25b742d0",
      "audio": ""
    },
    {
      "text": "Which of the following is essential for calculating insulin dose prior to a meal in type 1 diabetics?",
      "options": [
        {
          "label": "A",
          "text": "Glycemic index",
          "correct": false
        },
        {
          "label": "B",
          "text": "Glycemic load",
          "correct": false
        },
        {
          "label": "C",
          "text": "Insulin to carbohydrate ratio",
          "correct": true
        },
        {
          "label": "D",
          "text": "Preprandial blood glucose values",
          "correct": false
        }
      ],
      "correct_answer": "C. Insulin to carbohydrate ratio",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Insulin to carbohydrate ratio</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Glycemic index: While the glycemic index provides information about how quickly a food raises blood sugar, it is not directly used in calculating the insulin dose.</li><li>\u2022 Option A. Glycemic index:</li><li>\u2022 Option B. Glycemic load: Glycemic load combines the glycemic index with the amount of carbohydrate in a food. It can be helpful in meal planning, but the I:C ratio is the primary tool for calculating the insulin dose.</li><li>\u2022 Option B. Glycemic load:</li><li>\u2022 Option D. Preprandial blood glucose values: While important for determining the need for a correction dose of insulin, preprandial blood glucose values alone are not sufficient to calculate the mealtime insulin dose.</li><li>\u2022 Option D. Preprandial blood glucose values:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The insulin to carbohydrate ratio is essential for calculating the insulin dose for a meal in type 1 diabetes.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "d1c0f831",
      "audio": ""
    }
  ]
}